TABLE 3.

Univariate and multivariate analysis of risk factors for PFS and OS

	Progression‐free survival (n = 75, events = 51)				Overall survival (n = 75, events = 39)
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
Age (10‐years increase)	0.82 (0.65–1.04)	0.10	—	—	0.78 (0.59–1.02)	0.07	—	—
Sex (male vs. female)	1.30 (0.73–2.29)	0.37	—	—	1.37 (0.71–2.64)	0.34	—	—
ECOG (1+ vs. 0)	1.97 (1.06–3.68)	0.03	—	—	4.23 (1.75–10.2)	<0.01	2.83 (1.12–7.11)	0.03
Stage (III‐IV vs. I‐II)	1.54 (0.55–4.28)	0.41	—	—	2.24 (0.54–9.29)	0.27	—	—
Prev. indolent lymphoma (yes vs. no)	0.89 (0.47–1.67)	0.71	—	—	0.90 (0.44–1.85)	0.78	—	—
Primary refractory (yes vs. no)	2.19 (1.24–3.87)	<0.01	1.99 (1.12–3.55)	0.02	2.00 (1.04–3.86)	0.04	1.79 (0.90–3.56)	0.09
Bulky (>7 cm vs. <7 cm)	1.56 (0.88–2.75)	0.13	—	—	1.86 (0.96–3.58)	0.06	—	—
Cell of origin (Non‐GCB vs. GCB)	1.70 (0.93–3.09)	0.08	—	—	1.81 (0.92–3.57)	0.09	—	—
HGBL (yes vs. no)	0.99 (0.45–2.19)	0.98	—	—	1.31 (0.58–2.96)	0.52	—	—
Previous lines	1.05 (0.83–1.33)	0.69	—	—	1.17 (0.88–1.54)	0.28	—	—
IPI score	1.74 (1.30–2.31)	<0.001	*	*	1.79 (1.28–2.51)	<0.001	*	*
CAR T‐cell dose	0.81 (0.58–1.12)	0.21	—	—	0.69 (0.46–1.02)	0.07	—	—
CAR T‐cell dose/ kg (0.01‐units increase)	0.86 (0.68–1.07)	0.18	—	—	0.81 (0.62–1.06)	0.12	—	—
LDH (>2xULN vs. <2xULN)	2.70 (1.53–4.86)	<0.001	2.48 (1.40–4.40)	<0.01	3.92 (2.08–7.40)	<0.001	2.75 (1.38–5.46)	<0.01

*IPI score was not included in the multivariate analysis because of the high multicollinearity with other covariates. IPI score and CAR T‐cell dose were analyzed as continuous variables.

Abbreviations: CART, Chimeric Antigen Receptor T‐cell; ECOG, Eastern Cooperative Oncology Group; GCB, Germinal Center B‐cell; HGBL, High‐grade B‐cell lymphoma; IPI, International Prognostic Index; LDH, Lactate Dehydrogenase; ULN, Upper Limit of Normal.